INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeoGenomics, Inc. - NEO
NEONEW YORK, Aug. 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of NeoGenomics, Inc. ("NeoGenomics" or the "Company") (NASDAQ: NEO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeoGenomics, Inc. - NEO
NEONEW YORK, Aug. 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of NeoGenomics, Inc. ("NeoGenomics" or the "Company") (NASDAQ: NEO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The...
NEOGEN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Neogen Corporation - NEOG
NEONEW YORK and NEW ORLEANS, Aug. 15, 2025 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 16, 2025 to file lead plaintiff applications in a securities class action...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeoGenomics, Inc. - NEO
NEONEW YORK, Aug. 6, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of NeoGenomics, Inc. ("NeoGenomics" or the "Company") (NASDAQ: NEO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The...
NeoGenomics Will Debut Its PanTracer Family, A Comprehensive Suite Of Genomic Profiling Tests For Advanced Solid Tumors, At The 2025 American Society Of Clinical Oncology Annual Meeting In Chicago, May 30–June 3, 2025
NEONeoGenomics Announced The Commercial Launch Of c-MET CDx For NSCLC, Its C-MET Companion Diagnostic Immunohistochemistry (IHC) Assay
NEOA Look at NeoGenomics's Upcoming Earnings Report
NEOAssessing NeoGenomics: Insights From 9 Financial Analysts
NEOPiper Sandler Maintains Overweight on NeoGenomics, Lowers Price Target to $12
NEOMorgan Stanley Maintains Equal-Weight on NeoGenomics, Lowers Price Target to $10
NEOGoldman Sachs Maintains Buy on NeoGenomics, Lowers Price Target to $10
NEOLeerink Partners Downgrades NeoGenomics to Market Perform, Lowers Price Target to $9
NEONeedham Maintains Buy on NeoGenomics, Lowers Price Target to $8.5
NEONeoGenomics Raises FY2025 Adj EPS Guidance from $0.15-$0.19 to $0.16-$0.20 vs $0.18 Est
NEONeoGenomics Raises FY2025 Sales Guidance from $735.00M-$745.00M to $747.00M-$759.00M vs $739.39M Est
NEONeoGenomics Q1 Sales $168.03M Miss $170.96M Estimate
NEOInsights Ahead: NeoGenomics's Quarterly Earnings
NEONeoGenomics Validates PanTracer LBx, A Blood Test for Comprehensive Tumor Profiling
NEODeep Dive Into NeoGenomics Stock: Analyst Perspectives (5 Ratings)
NEOGoldman Sachs Maintains Buy on NeoGenomics, Lowers Price Target to $15
NEONeoGenomics Appoints Tony Zook As Chief Executive Office
NEONeoGenomics Promotes Warren Stone To President & COO, Effective April 1, 2025
NEONeoGenomics Acquired Pathline, Strengthening The Company's Commercial Presence In The Northeast U.S., Expanding Its Service Capabilities And Accelerating Growth In Molecular And Hematology-oncology Testing, Deal Terms Were Not Disclosed
NEOPiper Sandler Maintains Overweight on NeoGenomics, Lowers Price Target to $18
NEOB of A Securities Maintains Neutral on NeoGenomics, Lowers Price Target to $16
NEONeedham Maintains Buy on NeoGenomics, Lowers Price Target to $18
NEONeoGenomics Reaffirms FY25 Guidance For Consolidated Revenue Of $735M - $745M, Est $733.01M
NEONeoGenomics Q4 2024 Adj EPS $0.04 Beats $0.03 Estimate, Sales $172.00M Miss $173.18M Estimate
NEO5 Analysts Assess NeoGenomics: What You Need To Know
NEONeedham Reiterates Buy on NeoGenomics, Maintains $19 Price Target
NEONeoGenomics Sees FY25 Total Revenues $735M-$745M vs $727.7M Est.
NEOBenchmark Downgrades NeoGenomics to Hold
NEONeedham Reiterates Buy on NeoGenomics, Maintains $19 Price Target
NEONeoGenomics Shares Are Falling Today: What's Going On?
NEOShares of NeoGenomics, Inc. (NASDAQ: NEO) are, after the company announced that CEO Chris Smith will retire effective April 1 2025.
Neogenomics Announced That Chris Smith Will Retire As CEO And Board Member Effective April 1, 2025. Tony Zook, An Independent Board Member Since 2023, Will Assume The Role Of CEO At That Time
NEONeoGenomics To Present Four Studies At AMP 2024 Showcasing ctDNA And NGS Advancements For Cancer Diagnostics And Personalized Treatment
NEONeedham Reiterates Buy on NeoGenomics, Maintains $19 Price Target
NEONeoGenomics Reiterates FY24 Revenue Outlook In The Range Of $655M-$667M; Raises Adjusted EBITDA Guidance From $33M-$37M To $37M-$40M
NEONeoGenomics Q3 2024 Adj. EPS $0.05 Beats $0.01 Estimate, Sales $167.824M Beat $167.010M Estimate
NEOAnalyst Ratings for NeoGenomics
NEOAnalysts have provided the following ratings for NeoGenomics (NASDAQ:NEO) within the last quarter:
Raymond James Maintains Outperform on NeoGenomics, Lowers Price Target to $15
NEO